Herantis Pharma: Key takeaways from todays R&D update webinar
Herantis Pharma Plc, Press release, 19 January 2023 at 1:00 pm EST Antti Vuolanto, CEO of Herantis Pharma said, “We made good progress in 2022 achieving encouraging preclinical results and submitting clinical trial application (CTA) for HER-096. Pending CTA approval, we plan to create additional value in 2023 through early clinical development and to pursue partnering opportunities for HER-096. In December 2022, Herantis was selected to receive financing from European Innovation Council Accelerator program: a grant of €2.5 with the option to receive additional funding through an equity